Psilocybin‐assisted therapy reduces heavy drinking in patients with AUD
The Brown University Psychopharmacology Update November 3, 2022 DOI: 10.1002/pu.30946 via OpenAlex
Summary
AI-generated from the abstractTwo sessions of psilocybin-assisted psychotherapy reduced heavy-drinking days and other alcohol-related problems more than placebo plus psychotherapy in a randomized trial of patients with alcohol use disorder. No serious adverse events or psychotic disturbances occurred with psilocybin. Results appeared in JAMA Psychiatry.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Patients with alcohol use disorder |
| Topics | Addiction Psilocybin |
| Keywords | Adverse effect Placebo Hallucinogen |
| Key finding | Two sessions of psilocybin-assisted psychotherapy reduced heavy-drinking days and other alcohol-related problems compared to placebo plus psychotherapy. |
Abstract
Two sessions of psilocybin‐assisted psychotherapy resulted in reduced heavy‐drinking days and other alcohol‐related problems relative to placebo plus psychotherapy in a randomized trial involving patients with alcohol use disorder (AUD). There were no serious adverse events associated with psilocybin administration, and no signs of psychotic disturbances. Study results were published online Aug. 24, 2022, in JAMA Psychiatry .